NCT03742258 2025-06-18
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
Northwestern University
Phase 1 Completed
Clinical Trials
7 trialsNCT02000934 2023-02-08
A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies
Calithera Biosciences, Inc
Phase 1 Completed
NCT03238651 2023-02-08
A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)
Calithera Biosciences, Inc
Phase 1 Terminated
NCT03338881 2023-02-08
A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies
Calithera Biosciences, Inc
Phase 1 Withdrawn
NCT03357627 2023-02-08
A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma
Calithera Biosciences, Inc
Phase 1 Completed
NCT03359733 2023-02-08
A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor
Calithera Biosciences, Inc
Phase 1 Withdrawn
NCT03772288 2023-02-08
A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)
Calithera Biosciences, Inc
Phase 1 Withdrawn